Remy Cointreau warns of sharp fall in revenue in fiscal first half 2024, then recovery
By Adria Calatayud
Remy Cointreau SA on Friday forecast organic sales will remain stable in the year ahead after it reported higher sales for the fourth quarter and fiscal 2023 as a whole.
The French cognac maker said it anticipates a sharp sales decline in the first half of fiscal 2024, due to weakness in the U.S. and high year-earlier comparisons, and a strong recovery in the second half driven by a U.S. rebound that is expected to start in the third quarter.
It also intends to confirm its level of profitability in the fiscal year to March 2024 thanks to cost controls and a stabilization of the ratio of marketing and communication spending relative to sales.
The company, which makes Remy Martin cognac and Cointreau orange liqueur, said sales for the fourth quarter ended March amounted to 243.8 million euros ($268.9 million) compared with EUR227 million in the year-earlier period. On an organic basis, sales grew 10%.
Total sales for the year were EUR1.55 billion, up 10% on an organic basis.
Write to Adria Calatayud at adria.calatayud@dowjones.com
- Adria Calatayud
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-28-23 0210ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?